

Dear SAPA-CT Members and Friends:

On behalf of the Executive Committee of Sino-American Pharmaceutical Professionals Association - Connecticut (SAPA-CT), I would like to thank you all for coming to our 4th SAPA-CT annual conference. In this exciting one-day event, many industrial executives and academic experts will share their visions of the future pharmaceutical & biotech industries under the theme of "Adapting to the Changes in Biotech/Pharmaceutical Industry". We have a fantastic program covering hot topics including:

- Regulatory landscape and its impact on pharma/biotech industry
- Patent law and practice in biotech & pharma industry
- Global opportunities and partnering with CRO's
- Career development panel discussion-explore career options

I would like to take this opportunity to sincerely thank our members, volunteers, sponsors and friends for your participation and support. SAPA-CT is a relatively young chapter of the SAPA family. With your passions and contributions we are able to grow exponentially into a dynamic and influential organization that promotes scientific exchange and builds bridges between US and Chinese pharmaceutical industries.


This is a very fruitful year. We have expanded to more than 400 active members. We have successfully hosted the Scientific Symposium, the Career Development Workshop, the Summer BBQ, and the Connecticut Good Projects. It's time of the year again to get together appreciating our friendship, celebrating our achievements, and setting new goals to serve our SAPA-CT community. I would like you to take full advantage of this event: relax, enjoy, make new friends, and learn a bit of science.

Cheers! Steven Yu, PhD, MBA SAPA-CT President & 4th SAPA-CT Annual Conference Chair

SAPA-CT

Presidents

Liang Luo, Ph.D. (2015-2016)



Steven Yu, Ph.D., M.B.A. (2016-2017)



Jin Zhou, Ph.D. (2017-2018)



Conference Committee

Ming Cheng




Jasmin Huang




Chao Zhang



Chen Zhuo



Wenping Zhou



Xiang Gao

Yongmei Li

Alan Lin

Xiuling Lu

Rongliang Lou

Helen Luo

Xiaohui Mei

Li Wang

Yirong Wang

Minzhu Yin

Ruobing Xia

Ting Yi

Yong Yue

Xiaobo Zhong

Welcome

Session Chair: Steven Yu, Ph.D., M.B.A (8:40 – 9:00 am)

8:40 - 8:45 am

Steven Yu, Ph.D., President SAPA-CT (2016-2017)

8:45 - 8:50 am

Jin Zhou, Ph.D., President-elect SAPA-CT (2017-2018): Announcement of SAPA-CT Election results

8:50 - 8:55 am

Jijun Xing, Ph.D., Counselor of Science and Technology at China's Consulate General in New York

8:55 - 9:00 am

Joseph P. Ganim, Mayor of Bridgeport at Connecticut

Keynote Speech

Session Chair: Xiaobo Zhong, Ph.D. (9:00 – 9:40 am)

9:00-9:40 am

Tian Xu, Ph.D., Cyril Norman Hugh Long Professor, Vice Chairman, Genetics, Yale University "From Growth Regulation to Translation"

Section 1: Regulatory Landscape and its Impact on Pharma/Biotech Industry

Session Chairs: Huiping Jiang, Ph.D., Jin Zhou, Ph.D., Steven Yu, Ph.D., M.B.A, Chao Zhang (9:40 – 12:10 pm)

9:40-10:10 am

Joanne Palmisano, M.D., FACP, FRAPS, Vice President of Regulatory Affairs, Boehringer Ingelheim

"What's New in the Changing US Regulatory Environment?"

Morning Break (10:10 – 10:40 am)

10:40 - 11:10 am

Dan Zhang, M.D., MPH, Chairman and CEO, Fountain Medical Development Ltd.

"Clinical and Regulatory Strategy in the Era of ICH"

11:10 - 11:40 am

Justine Tan, M.B.A., Vice President, Strategic Partner at Evergtande Health

"Integrate Global Recourses to Improve Health Outcome"

11:40 - 12:10 pm

Andrew Luan, Ph.D., Deputy Team Leader, GenScript Inc.

"MonoRabTM Generating Rabbit Monoclonal Antibodies (mAbs) with Better Affinity and Specificity for Challenging Targets"

12:10 – 1:10 pm Complementary Lunch

Section 2: Patent Law and Practice in Biotech & Pharma Industry

Session Chairs: Xiuling Lu, Ph.D., Ting Yi, Ph.D., M.B.A, Zhuo Chen (1:10 – 2:40 pm)

1:10-1:40 pm

Vaibhav Saini, Ph.D., Licensing Director (Life Sciences), University of Connecticut

"Transforming Lab Research into Product for Public Benefit"

1:40 - 2:10 pm

Anthony Sabatelli, J.D., Ph.D., Partner, Dilworth IP, LLC. & Jing Zhou, Ph.D., Dilworth IP "Pharmaceutical Products: at the Intersection of Patent and Regulatory Law"

2:10 - 2:40 pm

John Jasper, Ph.D., Chief Executive Officer, Molecular Isotope Technologies, LLC

"The Use of Isotope Ratio Mass Spectrometry for Bio/Pharmaceutical Process Patent Protection"

Section 3: Global Opportunities and Partnering with CROs

Session Chairs: Wenping Zhou, Yongmei Li, Ph.D., Yan Zhang, Ph.D., Helen Luo, Ph.D. (2:40 – 5:25 pm)

2:40 - 3:10 pm

Ruobing Xia, M.B.A., President, Life Science Quest

"From Innovative Ideas to Viable Business - Real Case Study from Life Science Quest"

Afternoon Break (3:10 – 3:40 pm)

3:40 - 4:10 pm

Sean C. Xia, Ph.D., Senior Consultant, My Job Tank

"The AI solution for Recruiting International Talents"

4:10 - 4:40 pm

Qiang Zhang, Ph.D., CEO of SciTech Pharm

"Establishing a Pharmaceutical Company in China - Opportunities and Challenges"

4:40 - 5:10 pm

John Yao, Ph.D., Founder and CEO, TC Scientific Inc. & Daniel Holsworth, Ph.D., Director of Business Development and Regulatory Affairs, TC Scientific Inc.

"What We Bring to the Table: Partnering with a Chemistry CRO"

5:10 - 5:30 pm

Guanghui Hu, Ph.D., President & CEO, Admera Health, LLC

"Biomarker Guided Drug Development"

Panel Discussion: Career Delevopment – Explore Career Options

Session Chair: Yong Yue, Ph.D. (5:30 – 6:00 pm)

Panelists: Joanne Palmisano; Anthony Sabatelli; Ruobing Xia; Sean C. Xia; Dan Zhang; Qiang Zhang.

Closing Remarks

Jin Zhou. Ph.D. (6:00 – 6:05 pm)

Dinner Banquet

Hunan House, 32 Orange St, New Haven, CT (6:30 - 8:20 pm)

Dinner Talk Session Chair: Steven Yu, Ph.D., Jin Zhou. Ph.D.

6:50 – 7:00 pm

Service Award Ceremony

Speaker Biography

Jijun Xing, Ph.D.

Science and Technology Counselor, Chinese Consulate-General in New York

Dr. Xing Jijun, Science and Technology Counselor in Chinese Consulate-General in New York. He received a bachelor degree of engineering, Tianjing University, a master degree in economics, People's University of China and a PhD in administrative management, Huazhong S&T University. Dr. Xing has years of experience since 1990 in managing and facilitating international scientific and technological cooperation. He served in Chinese Embassies in Norway and the Netherlands, Director of



Asia and Africa and Director of Europe in the Chinese Ministry of Science and Technology (MOST). Before taking the current position, Dr. Xing served China Science and Technology Exchange Center as Deputy Director General covering governmental and nongovernmental cooperation in science and technology, technology transfer and academic exchanges. His personal academic interest includes low carbon development technologies and low cost health technologies etc. Dr. Xing is now still a strategic evaluation expert for international cooperation under European Horizon 2020 program.

Joseph P. GanimMayor of Bridgeport at Connecticut

Bridgeport Mayor Joseph Peter Ganim is now taking seventh term as Mayor of Connecticut's largest –Bridgeport. He was elected by a wide margin on November 3, 2015 to a position he had last held in 2003. When Ganim became Bridgeport's fiftieth mayor, he was the youngest person to hold the office in city history. Mayor Ganim had served six previous terms as chief executive of Bridgeport from 1991-2003, and in so doing accomplished several important things for the Park City. He managed a \$400 million annual operating budget and lead the city out of municipal bankruptcy by



overcoming a \$21 million budget deficit. He launched city's redevelopment efforts, including construction of Ballpark at Harbor Yard for a minor league baseball team, the building of Webster Bank Arena, and the redevelopment of industrial land on the city's waterfront. Also successfully leading an urban renewal project that relocated Housatonic Community College out of a deteriorated building and into a new \$60 million state-of-the-art downtown facility.

Tian Xu, Ph.D. CNH Long Professor and Vice Chairman,

Genetics at Yale University School of Medicine;

Investigator, Howard Hughes Medical Institute;

Prof Xu serves on the Overseas Advisory Committee of China State Council and was the President of the Chinese Biological Investigators Society and the Special Advisor to Yale President. Xu served on a dozen of editorial journal boards including "Cell", "Annual Review of Genetics" and "The International Journal of Biological Sciences". Xu is a pioneer and world leader of the field of growth regulation. His studies have not only elucidated fundamental principles of developmental biology, but also



revealed pathogenic mechanisms and contributed to the development of more than dozen drugs that are either approved by FDA or in clinical trials. Xu is an inventor and entrepreneur. He has developed multiple widely used genetic methods and is an inventor for dozens of patents, the chair of SAB for the Rothberg Institute and a founder and scientific advisor/consultant for multiple biotech companies.

Joanne Palmisano, M.D., FACP, FRAPS

Vice President, Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals Inc.

Dr. Palmisano currently serves as Vice President, Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals Inc. (BI), where she is responsible for oversight and leadership of the Regulatory Affairs organization in the US, including Regulatory Strategy for BI drug and biologic development programs, CMC, US Product Labeling, Promotion & Advertising Compliance, and Regulatory Submissions Operations. Prior to joining BI, Dr. Palmisano served as Assistant Vice President, Global Regulatory



Affairs and Regulatory Head for cardiovascular/metabolism, GI, and anti-Infective/ anti-Viral products at Wyeth/Pfizer. Her move into Regulatory Affairs followed several years at Merck as Sr. Medical Director of Clinical Development for Merck cardiovascular/lipid and & endocrinology products. Dr. Palmisano received her MD from Columbia University College of Physicians & Surgeons.

Dan Zhang, Ph.D. MPH

Chairman and CEO, Fountain Medical Development Ltd

Dr. Zhang is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with 1300 employees operating in China, South Korea, Japan, UK, India, Philippines, Armenia and USA. Dr. Zhang was the Head of Clinical Development at Sigma-Tau Research Inc, He is a member of grant application review committee for National Key Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development



Association. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of

Science and Technology of China, and was the secretary-general of the Association of "Thousand Talent" Expert. Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received an MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master's degree in healthcare management in 1998.

Justine Tan, MBA

Vice President, Strategic Partnerships at Evergrande Health

Justine Tan is the Vice President of Strategic Partnerships at Evergrande Health (HK0708), a subsidiary of Evergrande Group (HK3333), a Global Fortune 500 company. At the firm, she focuses on business and partnership developments, including new project evaluation and negotiation. Prior joining she has worked for some major players in the consume package goods industry for years, such as Daymon Worldwide and Pepsico. Data analysis, new product development, sales and marketing, business development and negotiation are some of her key responsibilities. Justine



graduated from Hunan University, China in 1997, received her MBA from Wake Forest University, North Carolina in 2000. Justine and her family live in Fairfield, CT.

Andrew Luan, Ph.D.

Deputy Team Leader, GenScript

Dr. Andrew Luan joined GenScript USA Inc in Jan. 2016, currently holding the position of Deputy Team Lead for protein and antibody related services. Prior to his current role, Andrew worked as a Science Analyst in Proactive Capital Group (PCG) in 2015. Andrew received his PhD degree in Biochemistry from State University of New York (SUNY) in 2014.



Vaibhav Saini, Ph.D.

Licensing Director (Life Sciences), University of Connecticut

As Licensing Director for Life Sciences at the University of Connecticut (UConn), Vaibhav puts his passion for transforming life sciences research into products to benefit society. He proactively engages faculty members at UConn with regional, national and international business and investment groups. He helps commercialize UConn technologies by focusing on patenting, marketing and licensing. He actively uncovers academic-industry



collaborative research opportunities and contributes towards start-up creation. Prior to UConn, he worked at Harvard Medical School, where as an Instructor in Medicine he researched hormonal regulation of osteoporosis (bone loss), alopecia (hair loss), and hepatic steatosis (fatty liver). In addition, he participated in the Johns Hopkins University Carey Business School INNoVATE program, and the Harvard Innovation and Commercialization course. He was also an intern for a year at Partners HealthCare Innovation in Boston.

Anthony Sabatelli, Ph.D. J.D.

Research Scientist and Patent Attorney, Dilworth IP

Dr. Anthony Sabatelli is an experienced patent practitioner and former biotech executive and research scientist, who provides insightful, practical, and business-oriented service to his clients. Having spent most of his career in-house, as both a research scientist and as a patent attorney, Dr. Sabatelli appreciates the needs and perspective of the inventors in the lab and the in-house attorneys who seek to protect those inventions. He listens to his clients to help them create robust, yet practical, portfolios, whether comprising a single patent case or several hundred patents. Above all, he enjoys sharing his passion for his work



with his clients and colleagues. Dr. Sabatelli has a strong interest in and commitment to education and is currently an Adjunct Professor of Chemistry at the University of New Haven. He is a Member of the Board of Governors of Yale University and currently serves as Immediate Past-Chairman of the Yale Graduate School Alumni Association. Dr. Sabatelli is also a Board member of CURE (Connecticut United for Research Excellence), which advocates for the bioscience industry here in the state, and chairs CURE's Government Affairs Committee.

Jing Zhou, Ph.D.Patent Agent, Dilworth IP

As a patent agent and former research scientist, with over 15 years of experience in top academic laboratories, Dr. Jing Zhou applies her extensive knowledge of mechanical engineering and biomaterials to the patent preparation and prosecution process. Dr. Zhou's background includes her doctoral research at the University of California, Berkeley on nanoscale mechanical testing solutions to evaluate wear and friction of biomedical polymer implants. Prior to joining Dilworth IP, Jing conducted research at the National Institute of Standards and



Technology (NIST). Dr. Zhou is a highly motivated biomedical scientist and engineer with a broad interest in biomedical engineering, mechanical engineering, and materials science. By combining her years of experience in the lab with her knowledge of patent law, she assists clients by translating their complex scientific ideas into strong patents.

John P. Jasper, Ph.D.

Chief Executive Officer, Molecular Isotope Technologies LLC

Dr. Jasper is the Chief Executive Officer of Molecular Isotope
Technologies LLC / Nature's Fingerprint® Authentication of Niantic,
Connecticut (www.NaturesFingerprint.com). Nature's Fingerprint / MIT
LLC performs product and process authentication on bio/pharmaceutical
products via natural-abundance stable isotopes that occur in all matter.
This firm has already protected more than \$2 billion of drugs against
process patent infringement. John received his B.A. in Geophysical
Sciences and Biological Sciences from The University of Chicago in 1981



and he subsequently received his Ph.D. from the Massachusetts Institute of Technology / Woods Hole Oceanographic Institution in Marine Organic Chemistry.

Ruobing Xia, MBA

President, Life Science Quest

Ruobing Xia oversees global strategy, business development, and commercial operations. An accomplished marketer, business development professional, and entrepreneur with extensive global experience, Ruobing co-founded several startups where she is responsible for global strategy, business development, and commercial operations. Previously, she had a progressive career with Eli Lilly and Boehringer Ingelheim where she managed hundred million dollar product launches and promotional budgets, developed sales and marketing strategies, and generated licensing deals. This was supported



by her earlier career in foreign trade, international banking, finance, and venture development. Ruobing holds Masters degrees in International Affairs (finance) from Columbia University in New York City and Business Administration (MBA) from IMD in Lausanne, Switzerland.

Sean C Xia, Ph.D.Senior Consultant, My Job Tank

Dr. Xia is the President of US-China Advanced Institute for International Business, Arbitrator of Shanghai Arbitration Commission, and the Senior Consultant of Dai & Associates. He is the Prof. of Chinese business law, the Senior Consultant of My Job Tank, Inc., the Vice-President of Chinese Biz News, the Vice-Chairman of China Association for International Economic Corporation, the Vice-President of Shanghai Overseas Returned Scholars Association(SORSA); Attoney-at-law and Senior Advisor in Dacheng-Dentons Law Offices. Professor Sean C. Xia is registered in the State Bar of California



and New York Supreme Court as a Foreign Legal Consultant in the law of China, he is also the visiting scholar of RAND Corporation. He has published several theoretical monographs and translation works. He used to be the visiting manager in Mckesson Corporation based in San Francisco, the scholar in Fudan University. He got the master degree in International Economic Law in Dalian Maritime University and is awarded the doctoral degree of Business Administration in Business School Netherlands.

Qiang Zhang, Ph.D.

CEO, SciTech Pharm


Dr. Qiang Zhang obtained his Ph.D. degree in physical chemistry at University of Pierre and Marie Curie in Paris, France. After graduation, he respectively spent four years doing postdoctoral research work at McGill University in Montreal (Canada) and at State University of New York in Stony Brook. In 1999, Dr. Zhang joined Boehringer Ingelheim Pharmaceuticals Inc., as a computational chemist in the structure research group, department of medicinal chemistry. During his sixteen years with the company, Dr. Zhang was involved in many research projects across



different therapeutics areas, such as autoimmune diseases and cardiovascular diseases. He was named as an inventor in thirteen patents. He served as the first treasurer at SAPA-CT. In 2015, Dr. Zhang cofounded Beijing SciTech-MQ Pharmaceuticals in China. He is currently the president and chief scientific officer of the company.

John Yao, Ph.D.Founder and CEO, TC Scientific Inc.

Dr Junhzi (John) Yao is founder and CEO of TC Scientific Inc., a chemistry centric leading CRO in Edmonton, Alberta Canada. Dr. Yao cofounded TC Scientific in 2009 and has over 20 years experience in organic synthesis and the chemical CRO business. TC Scientific has worked with wide variety of companies ranging from, virtual to large biotech and Pharmaceutical companies. Dr. Yao received his PhD degree in chemistry from Wuhan University. He obtained Postdoctoral Research training at the



Department of Chemistry at Southern Methodist University in Dallas and at the University of Manitoba, Canada.

Daniel Holsworth, Ph.D.

Director of Business Development and Regulatory Affairs ,TC Scientific Inc.

Dr. Daniel Holsworth, Ph.D., is Director of Business Development and Regulatory Affairs at TC Scientific. Formally trained as a synthetic & medicinal chemist, he has over 25 years' experience in the biotech & pharmaceutical industries, including a variety of senior level positions in both the traditional corporate and entrepreneurial arenas. Career highlights include his time as a Research Fellow at Pfizer, and founding three drug



discovery companies aimed at, respectively, regenerative medicine (StemNext), cancer therapies (ODIN), and cardiovascular treatments (P&H Therapeutics). He received his PhD from Wayne State University, and was a Post-Doctoral Fellow at Parke-Davis Pharmaceuticals. He recently added Regulatory Affairs to his areas of expertise with a certificate from University of California, San Diego.

Guanghui Hu, Ph.D.

President & CEO, Admera Health, LLC

Dr. Guanghui Hu is the President and CEO of Admera Health. Prior to that, Dr. Hu acquired over 15 years of drug development, molecular diagnostics and management experience in the biopharmaceutical industry at companies including Merck and GlaxoSmithKline. Dr. Hu completed postdoctoral research at the University of California Los Angeles after earning his Ph.D. from Baylor College of Medicine, holds a Master of Science degree from the Chinese Academy of Sciences, and a Bachelor of Science degree from Tsinghua University.



Sponsors











































Nucleosome Biotechnology Inc.

Parking information

